A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers
Status:
Completed
Trial end date:
2020-03-09
Target enrollment:
Participant gender:
Summary
The study is a randomized, single-dose, open-label, combined 2x2 dose and 3x3 dose crossover
design in fixed sequence. In this study, the relative bioavailability of different
formulations of AZD5718 will be assessed in healthy volunteers in order to compare the
exposure of Formulations A to D to the AZD5718 film-coated tablet formulation. The overall
treatment period will start with a 2-period, 2-dose treatment crossover, followed by a
3-period, 3-dose treatment crossover.